Divislab FY24 Annual Earnings Summary

Several custom synthesis and generic projects are awaiting FDA/EU approvals, which are outside Divi's control and could delay revenue recognition.

Management acknowledged potential impact of price pressures in US and European markets on operating margins, though they remain optimistic.

While raw material prices are currently softening, management noted that price variations could recur, especially for solvents like acetonitrile.

Custom synthesis growth depends on customer approvals and project timelines, which are uncertain and not quarter-to-quarter predictable.

Management acknowledged pricing pressure in large volume generics due to inventory destocking by mid-to-small players, which could last up to two years.

Despite management optimism, custom synthesis revenue appears flat YoY when adjusting for COVID sales, raising questions about growth trajectory.

Management noted a 30% spike in freight costs due to rerouting and war risk insurance, which could pressure margins in coming quarters.

Management indicated that generic API pricing pressure is cyclical and may take 2-3 quarters to stabilize, potentially impacting near-term revenue.

INR 20 crore inventory write-off was taken for COVID-related materials, indicating potential for further write-offs if demand does not recover.

Management cited potential consequences from ongoing geopolitical and economic fluctuations, though no specific impact was quantified.